Second-line therapy for advanced colorectal carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-06

AUTHORS

Naureen Starling, David Cunningham

ABSTRACT

The past decade has witnessed considerable advances in the treatment of colorectal cancer (CRC). The emergence and integration into clinical practice of new cytotoxic agents, such as irinotecan and oxaliplatin, has had a significant impact on outcomes from advanced CRC with median survivals of 18 to 21 months now achievable. Improvements in survival as a consequence of using these drugs as salvage therapies ultimately led to demonstration of efficacy for both in the first-line treatment of CRC. As the importance of second-line therapy is increasingly recognized, key issues, such as optimal schedules, chemotherapy combinations, and sequential therapy, need to be addressed. The integration of newer biologic agents, such as cetuximab and bevacizumab, for which recent data have emerged, has further added to the complexities of delivering therapy to patients with advanced CRC, heralding a new treatment era for this disease. More... »

PAGES

173-180

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11912-005-0070-5

DOI

http://dx.doi.org/10.1007/s11912-005-0070-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014362550

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15847707


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "Naureen", 
        "id": "sg:person.01136565472.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1054/bjoc.2000.1600", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006679595", 
          "https://doi.org/10.1054/bjoc.2000.1600"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-06", 
    "datePublishedReg": "2005-06-01", 
    "description": "The past decade has witnessed considerable advances in the treatment of colorectal cancer (CRC). The emergence and integration into clinical practice of new cytotoxic agents, such as irinotecan and oxaliplatin, has had a significant impact on outcomes from advanced CRC with median survivals of 18 to 21 months now achievable. Improvements in survival as a consequence of using these drugs as salvage therapies ultimately led to demonstration of efficacy for both in the first-line treatment of CRC. As the importance of second-line therapy is increasingly recognized, key issues, such as optimal schedules, chemotherapy combinations, and sequential therapy, need to be addressed. The integration of newer biologic agents, such as cetuximab and bevacizumab, for which recent data have emerged, has further added to the complexities of delivering therapy to patients with advanced CRC, heralding a new treatment era for this disease.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11912-005-0070-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021174", 
        "issn": [
          "1523-3790", 
          "1534-6269"
        ], 
        "name": "Current Oncology Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "second-line therapy", 
      "advanced colorectal cancer", 
      "colorectal cancer", 
      "new treatment era", 
      "new biologic agents", 
      "first-line treatment", 
      "advanced colorectal carcinoma", 
      "new cytotoxic agents", 
      "demonstration of efficacy", 
      "salvage therapy", 
      "sequential therapy", 
      "median survival", 
      "treatment era", 
      "chemotherapy combinations", 
      "biologic agents", 
      "colorectal carcinoma", 
      "clinical practice", 
      "therapy", 
      "cytotoxic agents", 
      "recent data", 
      "survival", 
      "treatment", 
      "bevacizumab", 
      "cetuximab", 
      "considerable advances", 
      "patients", 
      "carcinoma", 
      "oxaliplatin", 
      "agents", 
      "cancer", 
      "disease", 
      "months", 
      "drugs", 
      "efficacy", 
      "outcomes", 
      "past decade", 
      "significant impact", 
      "schedule", 
      "improvement", 
      "advances", 
      "practice", 
      "combination", 
      "data", 
      "consequences", 
      "demonstration", 
      "impact", 
      "importance", 
      "decades", 
      "emergence", 
      "era", 
      "optimal schedule", 
      "issues", 
      "key issues", 
      "integration", 
      "complexity"
    ], 
    "name": "Second-line therapy for advanced colorectal carcinoma", 
    "pagination": "173-180", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014362550"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11912-005-0070-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15847707"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11912-005-0070-5", 
      "https://app.dimensions.ai/details/publication/pub.1014362550"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_411.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11912-005-0070-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-005-0070-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-005-0070-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-005-0070-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-005-0070-5'


 

This table displays all metadata directly associated to this object as RDF triples.

143 TRIPLES      21 PREDICATES      86 URIs      77 LITERALS      11 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11912-005-0070-5 schema:about N0034c682715244ca853d9293497f86c6
2 N0b2a85e075f442b6beab87b54370ae81
3 N850412d1732d42d4916b7e08eb796bcc
4 Nd70b33d98e514a9fa7ab6f88ad770bd8
5 anzsrc-for:11
6 anzsrc-for:1112
7 schema:author N4cafe695e51945909386ff17b93608c0
8 schema:citation sg:pub.10.1054/bjoc.2000.1600
9 schema:datePublished 2005-06
10 schema:datePublishedReg 2005-06-01
11 schema:description The past decade has witnessed considerable advances in the treatment of colorectal cancer (CRC). The emergence and integration into clinical practice of new cytotoxic agents, such as irinotecan and oxaliplatin, has had a significant impact on outcomes from advanced CRC with median survivals of 18 to 21 months now achievable. Improvements in survival as a consequence of using these drugs as salvage therapies ultimately led to demonstration of efficacy for both in the first-line treatment of CRC. As the importance of second-line therapy is increasingly recognized, key issues, such as optimal schedules, chemotherapy combinations, and sequential therapy, need to be addressed. The integration of newer biologic agents, such as cetuximab and bevacizumab, for which recent data have emerged, has further added to the complexities of delivering therapy to patients with advanced CRC, heralding a new treatment era for this disease.
12 schema:genre article
13 schema:isAccessibleForFree false
14 schema:isPartOf N6b8baf18ed7c49eabe7c02f66285abfa
15 Nb1e30da950514e9da0e69895bf608155
16 sg:journal.1021174
17 schema:keywords advanced colorectal cancer
18 advanced colorectal carcinoma
19 advances
20 agents
21 bevacizumab
22 biologic agents
23 cancer
24 carcinoma
25 cetuximab
26 chemotherapy combinations
27 clinical practice
28 colorectal cancer
29 colorectal carcinoma
30 combination
31 complexity
32 consequences
33 considerable advances
34 cytotoxic agents
35 data
36 decades
37 demonstration
38 demonstration of efficacy
39 disease
40 drugs
41 efficacy
42 emergence
43 era
44 first-line treatment
45 impact
46 importance
47 improvement
48 integration
49 issues
50 key issues
51 median survival
52 months
53 new biologic agents
54 new cytotoxic agents
55 new treatment era
56 optimal schedule
57 outcomes
58 oxaliplatin
59 past decade
60 patients
61 practice
62 recent data
63 salvage therapy
64 schedule
65 second-line therapy
66 sequential therapy
67 significant impact
68 survival
69 therapy
70 treatment
71 treatment era
72 schema:name Second-line therapy for advanced colorectal carcinoma
73 schema:pagination 173-180
74 schema:productId N38a918bb0dc74212a6422d54f78a11dd
75 N3c6fe22b00654e399c408dee2ab8327d
76 Nad0a0d4db5bd421e82b7fe290a8785d2
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014362550
78 https://doi.org/10.1007/s11912-005-0070-5
79 schema:sdDatePublished 2022-10-01T06:33
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N3ab628558cc64ada8d1b003345290bbb
82 schema:url https://doi.org/10.1007/s11912-005-0070-5
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N0034c682715244ca853d9293497f86c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 N0b2a85e075f442b6beab87b54370ae81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Antineoplastic Agents
91 rdf:type schema:DefinedTerm
92 N38a918bb0dc74212a6422d54f78a11dd schema:name dimensions_id
93 schema:value pub.1014362550
94 rdf:type schema:PropertyValue
95 N3a80417c382d48a283df1d0753cabec0 rdf:first sg:person.01320161130.16
96 rdf:rest rdf:nil
97 N3ab628558cc64ada8d1b003345290bbb schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 N3c6fe22b00654e399c408dee2ab8327d schema:name doi
100 schema:value 10.1007/s11912-005-0070-5
101 rdf:type schema:PropertyValue
102 N4cafe695e51945909386ff17b93608c0 rdf:first sg:person.01136565472.17
103 rdf:rest N3a80417c382d48a283df1d0753cabec0
104 N6b8baf18ed7c49eabe7c02f66285abfa schema:volumeNumber 7
105 rdf:type schema:PublicationVolume
106 N850412d1732d42d4916b7e08eb796bcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Colorectal Neoplasms
108 rdf:type schema:DefinedTerm
109 Nad0a0d4db5bd421e82b7fe290a8785d2 schema:name pubmed_id
110 schema:value 15847707
111 rdf:type schema:PropertyValue
112 Nb1e30da950514e9da0e69895bf608155 schema:issueNumber 3
113 rdf:type schema:PublicationIssue
114 Nd70b33d98e514a9fa7ab6f88ad770bd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Neoplasm Staging
116 rdf:type schema:DefinedTerm
117 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
118 schema:name Medical and Health Sciences
119 rdf:type schema:DefinedTerm
120 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
121 schema:name Oncology and Carcinogenesis
122 rdf:type schema:DefinedTerm
123 sg:journal.1021174 schema:issn 1523-3790
124 1534-6269
125 schema:name Current Oncology Reports
126 schema:publisher Springer Nature
127 rdf:type schema:Periodical
128 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.424926.f
129 schema:familyName Starling
130 schema:givenName Naureen
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
132 rdf:type schema:Person
133 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.424926.f
134 schema:familyName Cunningham
135 schema:givenName David
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
137 rdf:type schema:Person
138 sg:pub.10.1054/bjoc.2000.1600 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006679595
139 https://doi.org/10.1054/bjoc.2000.1600
140 rdf:type schema:CreativeWork
141 grid-institutes:grid.424926.f schema:alternateName Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK
142 schema:name Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK
143 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...